Audit: QRS - 5-MeO-DMT for Health & Longevity
Audit conducted on 06/09/2026 01:51 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every cell traces to ER text: protocol cells to ER 349/351/363, time cells to ER 405/156/162/168, benefit and risk tiers to the ER #### headings, monitoring table to the ER biomarker table (ER 437-444), cadence to ER 433. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | marker_8_target keeps “No established target”; action_2_sub keeps “smaller symptom changes than escalating inhalation”; at_a_glance keeps “remain unresolved”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Absolute contraindications (MAOIs, harmala) stay in the stop gate; SSRIs/SNRIs stay in the caution gate as in ER 300. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates come only from ER Key Interactions & Contraindications; monitoring and qualitative items only from the ER Monitoring Protocol & Defining Success section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Only “GH Research” and “Beckley Psytech protocol” appear; both are in the same ER protocol bullets (ER 349, 351). No PMIDs or NCT IDs. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution beyond the two sponsor names already carried in the ER protocol labels. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Neutral, evidence-first register matching the ER, including its explicit sponsor-conflict framing. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Protocol and cadence cells are descriptive of what trials did, not instructions. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Abbreviations are expanded as in the ER (“New York Heart Association”, “corrected QT”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Preparation/integration schedule and full screening panel are retained rather than simplified away. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | at_a_glance names the unresolved durability and sponsor-data reliance, matching the ER’s weighting. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register throughout; the plain-language wording in at_a_glance is required by 7.4 and is carried from the ER Conclusion. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present verbatim at lines 446, 491, 542, 570, 600, 634, 664, 668-670, 796; tier labels at 546/551/556/560 and 638/644/648/655. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variables present; the only additions are the repeatable marker_#/qualitative_item_# rows the template defines. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans (website=”evidence_review”, “audit”, “full_review”) are byte-identical to the template; head and CSS diff clean apart from page_title. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped into the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1/2/3_label reproduce ER 349/351/363 bold labels verbatim; monitoring row labels reproduce the ER biomarker column verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Protocol cell labels and all eight marker names are unaltered. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file; the ER’s “⚠️ Conflicted” marker on Reactivations is correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed relative to the ER (benefit and risk tiers collapsed to single lines, interaction bullets stripped to label plus drug list, qualitative rationales trimmed) while keeping the qualifiers 8.5/9.5 forbid dropping. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- line 3, closing --- line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, which the embedded colon requires. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: 5_meo_dmt_2026-0906-0008_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: 2026-0906-0128. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | No qualifier appended. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “5-MeO-DMT for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0906-0128 → 09/06/2026 at line 421. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header block is byte-identical to the template apart from the two variables. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses ER 475-479: what it is, the depression and alcohol signals, the dominant harms, the open questions. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a separate sentence of the ER Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “low mood” for depression, “briefly dissolves the sense of self” for ego dissolution, “firms that profit” for sponsor conflict. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | Only “Company-run hospital trials” and “a small open study”. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers at all. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from ER 296-298 (absolute contraindications) and 316-327 (populations who should avoid). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All ten ER “populations who should avoid” bullets are present; the MAOI/harmala bullet is merged with the two ER absolute contraindications into item 1. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Ten <li> elements, lines 573-595. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dashes or trailing clauses; ER wording such as “on repeated seated measurement” and “Moderate to severe” is trimmed. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | ≥160/≥100 mmHg, <6 months, NYHA III or IV, QT >500 ms, 12 months, 2 years, Child-Pugh B or C all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in these parentheses; “>500 ms” is a numeric threshold, not a severity ordering. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names such populations and the section is populated accordingly. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from ER 300-314. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight non-contraindication ER interaction bullets are present; the two absolute-contraindication bullets are correctly excluded. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements, lines 603-624. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “— prescription” and “— over-the-counter and botanical” suffixes and all mechanistic rationale are stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER example-drug list is retained, trimmed only where the ER added descriptors (“dextromethorphan cough preparations” → “dextromethorphan”). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction parentheses contain plain comma-separated drug lists only. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names ten such interactions and the section is populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from the ER Therapeutic Protocol section (ER 349, 351, 363). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The regimen that carried the phase 2b result, the alternative fixed intranasal regimen, and the preparation/integration schedule the ER calls “the design feature most associated with larger effects”. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names more than three; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Lines 450-487; no placeholder text remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Depressive symptoms (ER 405), alcohol consumption (ER 156), anxiety/stress/life satisfaction (ER 162, 168). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | High tier first, then the two Medium-tier domains in ER order. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects exist; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Lines 497-534; no placeholder text remains. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All seven ER benefit headings are represented across the four tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four present at lines 544, 549, 555, 558. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is the bare ER heading text; the ER’s Magnitude: lines are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any benefits variable. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER tiers contain items. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All ten ER risk headings are represented across the four tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four present at lines 636, 643, 646, 653. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is the bare ER heading text; the ER’s Magnitude: lines and percentages are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s “(Spontaneous Re-Experiencing)” parenthetical on Reactivations is stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER tiers contain items. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER Monitoring Protocol & Defining Success table (ER 435-444) and cadence paragraph (ER 433). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER rows present: seated blood pressure, resting heart rate, 12-lead ECG corrected QT, ALT, hs-CRP, PHQ-9, GAD-7, CYP2D6 genotype. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 786-790, condensed from ER 433 with all intervals retained. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER’s qualitative-marker list (ER 448-453). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present at lines 799-822, each trimmed of its trailing rationale clause. |
Issues 06/09/2026 01:51
Pass rate 100.00%. No issues found.
Issues 06/09/2026 01:48
- 1.3 — Contraindication qualifiers dropped: QRS line 589 states “heart failure (New York Heart Association III or IV)” where ER line 322 restricts this to “decompensated heart failure”, and QRS line 595 states “Alcohol or substance use disorder outside supervised treatment” where ER line 327 says “Current alcohol or substance use disorder”; both omissions broaden the ER’s contraindication.
Fixes 06/09/2026 01:48
- 1.3 — Contraindication qualifiers restored: Restored the ER’s severity qualifier in the cardiac contraindication, changing “heart failure (New York Heart Association III or IV)” to “decompensated heart failure (New York Heart Association III or IV)”, and restored the temporal qualifier in the substance-use contraindication, changing “Alcohol or substance use disorder outside supervised treatment” to “Current alcohol or substance use disorder outside supervised treatment”.
Issues 06/09/2026 01:40
- 1.1 — Wrong direction for anxiety ratings: [time_3_sub] (line 535) says ratings “remained above baseline” for a cell covering “Anxiety, stress and life satisfaction”, but the ER states anxiety and stress ratings “remained lower at four weeks” (line 164) and only life satisfaction “remained above baseline” (line 170).
- 4.5 — Sheet overruns one A4 page: At the template’s own print metrics the content estimates to roughly 1.9 A4 pages; the Contraindications gate (lines 576–601), the eight-row Monitoring table with its three-line cadence sentence (lines 684–801), and the protocol/time sub-lines all exceed their per-section budget.
- 9.4 — Route clause retained on CYP2D6 item: Line 615 reads “CYP2D6 inhibitors, prescription (paroxetine, …)”, carrying the ER’s post-em-dash “— prescription” clause (ER line 304) through as a trailing comma clause instead of stripping it.
Fixes 06/09/2026 01:40
- 1.1 — Wrong direction for anxiety ratings: [time_3_sub] changed from “Ratings reached significance at four weeks after a single inhalation and remained above baseline” to “Anxiety and stress ratings fell and life satisfaction rose, both still changed four weeks after a single inhalation”, matching the ER’s stated direction for each outcome.
- 9.4 — Route clause retained on CYP2D6 item: The caution item was changed from “CYP2D6 inhibitors, prescription (paroxetine, …)” to “CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine, terbinafine)”, stripping the ER’s post-em-dash route clause while keeping the example drug list.
- 4.5 — Sheet condensed toward the one-page budget: Every over-budget section was tightened without dropping any item mandated by 8.2, 9.2, 14.2 or 15.2 — contraindications and interactions were reworded and their example lists trimmed (26 → 21 and 20 → 17 wrapped lines), the three protocol and two time-to-effect sub-lines were shortened, the monitoring cadence sentence and the marker 2, 5 and 8 cells were compressed, and two qualitative items lost their trailing clauses. All thresholds, time windows, severity classes and drug lists were preserved.
Issues 06/09/2026 01:34
- 13.4 — Parenthetical kept, primary term dropped: [risks_medium] (line 654) uses “Spontaneous re-experiencing”, the parenthetical of the ER heading “Reactivations (Spontaneous Re-Experiencing) ⚠️ Conflicted”, instead of stripping the parenthetical and keeping the ER’s primary term “Reactivations”.
Fixes 06/09/2026 01:34
- 13.4 — Parenthetical stripped from risk label: [risks_medium] changed from “Spontaneous re-experiencing” to “Reactivations”, keeping the ER heading’s primary term and dropping the parenthetical.